U.S. Court of Appeals for the Federal Circuit Chief Judge Sharon Prost.
The Federal Circuit ruled that Merck subsidiary Idenix claimed billions of potential compounds, leaving researchers with only a needle in a haystack. The decision wipes out what defendant Gilead Sciences had called the largest jury award in patent history.
October 30, 2019 at 04:46 PM
1 minute read
The U.S. Court of Appeals for the Federal Circuit will not revive a $2.5 billion jury award that Merck & Co. and subsidiary Idenix Pharmaceuticals won against Gilead Sciences in 2016.
The Federal Circuit agreed with U.S. District Judge Leonard Stark of the District of Delaware that Idenix’s 7,608,597 patent claimed far too many potential compounds to identify the specific 2′-methyl-up modified nucleoside that Gilead uses to treat hepatitis C.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
At NJM, a top-rated insurance company, we are seeking an Attorney on our Workers Compensation legal team with between 3 and 5 years of expe...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
